### **Criteria for Testing**

- 1. Pregnant women who (a) traveled while pregnant to an area with Zika transmission\* OR (b) had unprotected sex with a partner who spent time in an area with Zika transmission\*
- 2. Persons who developed compatible symptoms during or within 4 weeks of travel to an area with Zika transmission\*
- **3.** Persons who developed compatible symptoms<sup>1</sup> during or within 4 weeks of possible sexual exposure to Zika virus (e.g., sexual contact with a partner with symptomatic Zika virus disease or with history of travel to an area with active Zika transmission\*)
- **4.** Neonates with suspected or confirmed microcephaly or intracranial calcifications born to women who (a) traveled to an area with Zika transmission\* while pregnant or (b) had unprotected sex during pregnancy with a partner who spent time in an area with Zika transmission\* AND neonates without microcephaly or intracranial calcifications whose mother has positive or inconclusive Zika virus testing.
- **5.** Anyone who developed Guillain-Barre syndrome after spending time in an area with active Zika transmission\* or who had unprotected sex with a partner who spent time in an area with Zika transmission\*
- \* For up-to-date information about areas with Zika transmission, refer to CDC website: http://www.cdc.gov/zika/geo/index.html



Testing for Zika virus infection is now available from several commercial clinical laboratories. Most Zika virus testing (criteria 1-3 above) can now be performed using a commercial laboratory rather than the Department of Health

laboratory. DOH Laboratories should still be used for testing for patients meeting criteria 4 and 5 above as well as for testing of placental/fetal tissues collected at delivery or pregnancy termination (elective or spontaneous) for women with laboratory evidence of Zika virus infection during pregnancy and for testing of persons with possible unusual modes of Zika virus transmission (e.g., transfusion or organ transplantation). Testing by the DOH may also be considered for patients meeting criteria 1-3 whose insurance does not cover the cost of Zika virus testing at a commercial laboratory.

#### **Testing at a Commercial Laboratory**

#### Order Zika virus testing

- In general, rRT-PCR testing of both serum AND urine is recommended.
- Serologic testing (i.e., IgM antibody testing) is also generally recommended because the level of viremia and viruria declines over time and thus a negative rRT-PCR result does not exclude Zika virus infection.
- For more guidance about Zika virus testing refer to: <a href="http://www1.nyc.gov/assets/doh/downloads/pdf/cd/zika-testing-guidance-for-providers.pdf">http://www1.nyc.gov/assets/doh/downloads/pdf/cd/zika-testing-guidance-for-providers.pdf</a>

**Collect samples** as specified by commercial laboratory

- 1. Blood
- 2. Urine

Send specimens to commercial laboratory for testing

**Report ALL positive Zika virus test results** to the local Department of Health

## **Testing at DOH Laboratory**

Contact the local health department where the patient resides to discuss case and request testing.<sup>2</sup>

www.health.ny.gov/contact/contact\_information/

If testing approved, DOH will provide (via email) a Zika testing authorization form.

For outpatient testing, advise patient to call their local health department's specimen collection site to arrange for specimen collection at the specimen collection site.

The local DOH will provide information regarding the specimen collection site(s) and telephone numbers during the initial test request call.

# Provide patient with a completed "NYSDOH Infectious Diseases Requisition (IDR)" form available at:

 $(http://www.wadsworth.org/sites/default/files/WebDoc/1065760803/infectious\_diseases\_requisition\_DOH\_4463.pdf)$ 

Patient must take the NYSDOH IDR form AND the authorization form to the specimen collection center.

<sup>1</sup>Symptoms compatible with Zika virus infection include: fever, maculopapular rash, arthralgia, conjunctivitis

<sup>2</sup>Be prepared to provide patient demographic information, travel, and symptom information (e.g., dates and locations of travel, date of symptom onset), ordering provider information.

More information is available on the NYP Infonet: <a href="https://infonet.nyp.org/EPI/Pages/ZikaVirus.aspx">https://infonet.nyp.org/EPI/Pages/ZikaVirus.aspx</a>